Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

ABSTRACT:

Background

The purpose of the study was to assess the outcome of patients with advanced melanoma treated with matched molecularly targeted therapy.

Patients and methods

We reviewed 160 consecutive patients with metastatic melanoma treated in the phase I program (N = 35 protocols). Treatment was considered to be 'matched' (N = 84) if at least one drug in the regimen was known to inhibit the functional activity of at least one of the patient's mutations.

Results

Of 160 patients, 134 (83.7%) had adequate tissue for molecular analysis; 69% (110 of 160) had ≥1 mutation: 61.2% (82 of 134), BRAF; 20.7% (23 of 111), NRAS; 2.6% (2 of 77), KIT; 2.3% (1 of 44), KRAS; 20% (1 of 5), GNAQ; 11.1% (1 of 9), P53 and 2.6% (1 of 39), coexisting mutations in BRAF and PIK3CA. Eighty-four

SUBMITTER: Henary H 

PROVIDER: S-EPMC4081655 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature